
Kyverna Therapeutics is a patient-centered, clinical-stage biopharmaceutical company developing cell therapies for patients suffering from autoimmune diseases. Guided by our core values, Stay True to Why, Collaborate to Accelerate, Lead with Clarity, Boldly Innovative, and Own the Outcome, we are committed to transforming the future of treatment for autoimmune disease. Join us at the forefront of cell therapy innovation and help redefine what’s possible.
Title: Sr. Contracts Counsel
Reports to: Associate General Counsel
Location: Remote (West coast hours preferred)
Kyverna is seeking an in-house Sr. Contracts Counsel, who will be an integral member of the Legal Department. The Sr. Contracts Counsel will contribute in a strategic legal advisory capacity, supporting the AGC, and the Clinical Development team with contract negotiation, as well as assisting with the development of contracting standards, processes, and strategy in support of the Company’s strategic objectives. In addition, the Sr. Contracts Counsel will ensure contracts adhere to company policy and help develop standard templates. While this role will collaborate closely the Clinical Development organization, it will require cross-functional collaboration with team members from all functions of the company.
The national base salary range for candidates for this position is $200K to $235K annually. This salary range is an estimate of what we reasonably expect to pay for this posted position, and the actual salary may vary based on various factors that may include but are not limited to quality and length of experience, education, geographic location and alignment with market data.

Kyverna is a patient-centered, clinical-stage biopharmaceutical company focused on developing cell therapies for patients suffering from autoimmune diseases. Our lead product candidate, KYV-101 is advancing through clinical development across two broad areas of autoimmune disease: rheumatology and neurology, including Phase 2 trials for stiff-person syndrome, multiple sclerosis and myasthenia gravis, a Phase 1/2 trial for systemic sclerosis, and two ongoing multi-center, open-label Phase 1/2 trials in the United States and Germany for patients with lupus nephritis.
Kyverna’s pipeline includes next-generation chimeric antigen receptor (CAR) T-cell therapies in both autologous and allogeneic formats with properties intended to be well suited for use in B cell-driven autoimmune diseases.